Observational Study
Copyright ©The Author(s) 2020.
World J Gastrointest Endosc. Sep 16, 2020; 12(9): 285-296
Published online Sep 16, 2020. doi: 10.4253/wjge.v12.i9.285
Table 2 Patient outcomes among different groups
Half and half stents, n (%)Fully covered stents, n (%)Un-covered stents, n (%)P value
Successful deployment70/70 (100)70/70 (100)70 /70 (100)
Procedure related complications
Major adverse events and or mortality00000
pancreatitis6 (8.6 )5 (7.1)5 (7.1)0.93
Minor bleeding4 (5.7)3 ( 4.3)5 (7.1)0.77
Post-ERCP complications
Occlusion13 (18.6)12 (17.1)11 (15.7)0.9
Early stent adverse effect, within 1 mo1 (1.4)4 (5.7)1 (1.4)0.21
Sludge formation9 (12.9)7 (11.1)1 (1.4)0.04
Tumor Ingrowth0 (0.0)0 (0.0)10 (14.3)0.00003
Tumor Overgrowth4 (5.7)5 (7.1)0 (0.0)0.09
Cholangitis due to stent occlusion7 (10.0)8 (11.4)7 (10.0)0.95
Cholecystitis0 (0.0)4 (5.7)0 (0.0)0.02
Migration0 (0.0)6 (8.6)0 (0.0)0.002
Stent patency in d, median (95%CI)614 (390.6-780.1)256.0 (167.5-315.4)1,2536 (323.1-743.9)0.02
Follow-up in d, median (range)112 (5-613)109 (7-621)108 (7-541)0.82
Overall survival in d, median (95%CI)129 (96.8-167.1)114.0 (92.7 -165.4)119.0 (89.9-160.1)0.20